Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma.
about
Monitoring of the Immune Dysfunction in Cancer PatientsA phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic responseIDO and galectin-3 hamper the ex vivo generation of clinical grade tumor-specific T cells for adoptive cell therapy in metastatic melanomaA versatile system for rapid multiplex genome-edited CAR T cell generationPrognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix.CTLA4 blockade reduces immature myeloid cells in head and neck squamous cell carcinoma.Gene silencing of indoleamine 2,3-dioxygenase 2 in melanoma cells induces apoptosis through the suppression of NAD+ and inhibits in vivo tumor growth.A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response.Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.Early Immune Regulatory Changes in a Primary Controlled Human Plasmodium vivax Infection: CD1c+ Myeloid Dendritic Cell Maturation Arrest, Induction of the Kynurenine Pathway, and Regulatory T Cell Activation.Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms.A flowcytometric analysis to efficiently quantify multiple innate immune cells and T Cell subsets in human blood.Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis.Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous MelanomaDisease-Associated Plasmacytoid Dendritic Cells.Discovery of IDO1 Inhibitors: From Bench to Bedside.Comprehensive T-cell immunophenotyping and next-generation sequencing of human papillomavirus (HPV)-positive and HPV-negative head and neck squamous cell carcinomas.Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.Systemic BRAF/MEK Inhibitors as a Potential Treatment Option in Metastatic Conjunctival Melanoma.Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward.Immune Cell Metabolism in Tumor Microenvironment.Indoleamine 2,3 dioxygenase as a prognostic and follow-up marker in melanoma. A comparative study with LDH and S100B.Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma.Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a "Hammer" and "Anvil".New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1
P2860
Q28072712-52C71DC2-6497-4B7B-8089-52D30E636703Q32177609-9FE515C0-9090-4264-A1F5-40C5B500A957Q33849567-FC16A472-87F1-48D4-92FB-FE23D6D572B0Q34047977-43E1C9D9-5440-4EDC-A2A1-4D97BB939E93Q37061685-0F03ED3C-5716-4AA6-A876-1769C3A475E3Q37079094-8101D284-AEA7-4106-93D6-FF05F23FABF3Q37362666-7A8611B0-AD9E-46BA-856C-87D26A5B9867Q37615827-9A405ED8-38F2-48EB-B1D9-F780736666ECQ38700735-62C42BAA-61EC-49F1-B6D5-E8DBADDC3D0BQ38892525-3EE90AF7-10E1-42B0-837F-2E9595451218Q39072004-CC865535-0B0F-4DF3-898F-379F10C22D9CQ40306485-A96D67CF-8098-4EE5-BF10-8E6B924E0BD4Q40939669-DE99BF8A-DA76-4B68-8FB1-A99992BCFD7CQ42362520-91DDC7BB-105C-4FAE-A2AE-C7BD87338F84Q43930865-3E8553E1-346E-4B83-B73C-10BB3EEE67A8Q47547812-C524FBDC-8FF0-4FF2-B7D9-63DDC462D1ABQ47683846-1735DE8C-EA14-4250-956F-B3B18AB3A1E3Q47821123-F2BB2A93-7CD8-440E-9F04-45DF98589206Q47966722-BE13107D-9F59-4366-B141-0205332C82DDQ49280922-1B75D863-B731-4BCF-AA28-DA02ED4AD000Q50217783-A3FCB82F-E7D1-4025-A070-72A8D0750CC1Q51502194-FAF2503C-670C-46A8-9C7D-341AB647513FQ53068034-6904665B-C021-409B-AD36-28FB74DFF113Q54378300-BCA8E24B-6FC1-4D53-B2E6-EA67198A8A74Q58740200-86C4F573-27C3-4F4B-9DBC-3D14EDB2597C
P2860
Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma.
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Characterization of the in viv ...... ting immune cells in melanoma.
@ast
Characterization of the in viv ...... ting immune cells in melanoma.
@en
type
label
Characterization of the in viv ...... ting immune cells in melanoma.
@ast
Characterization of the in viv ...... ting immune cells in melanoma.
@en
prefLabel
Characterization of the in viv ...... ting immune cells in melanoma.
@ast
Characterization of the in viv ...... ting immune cells in melanoma.
@en
P2093
P2860
P50
P1433
P1476
Characterization of the in viv ...... ting immune cells in melanoma.
@en
P2093
I Chevolet
M Schreuer
M Van Gele
N van Geel
R Speeckaert
P2860
P304
P356
10.4161/2162402X.2014.982382
P577
2015-03-01T00:00:00Z